Breaking AI & Tech News Analyzed

Translated Fiction Review Roundup A collection of recent translated fiction has been reviewed, showcasing the diversity and complexity of global literature. The reviews include: 'Sisters in Yellow' by Mieko Kawakami Sisters in Yellow by Mieko Kawakami, translated by Laurel Taylor and Hitomi Yoshio (Picador, £16.99) Kawakami’s latest opens with a bang, as narrator Hana learns that her old friend Kimiko has been charged with abduction. This MacGuffin takes us to their friendship in late-1990s Tokyo, when teen Hana and the older woman open a bar called Lemon: “Yellow attracts money.” But it’s a turbulent ride and soon Hana is in a world of organised crime. “The world is crazy. I feel like I’m living in a manga.” She’s not the only one, and you need an appetite for Kawakami’s style, which prefers to explore rather than explain – people come and go, buildings burn down, cancer is diagnosed, almost at random – but the relentless rush means there’s no time to get bored. At its best – as in a scene where Hana’s unreliable mother wants to borrow 2m yen for investment in lingerie that helps “your spine and organs move back to where they’re supposed to be” – this is a story both absurd and horrifying. 'All Flesh' by Ananda Devi All Flesh by Ananda Devi, translated by Jeffrey Zuckerman (Pushkin, £12.99) “Forgive me for starting this story with bodily, unpalatable origins.” You may as well – it’s all like that. In an unnamed European country, a schoolgirl “born with no urge but to consume” is getting bigger and bigger. “My gut, my ass, my thighs – they were all set on reaching the farthest corners of the world.” She blames her gluttony on the need to silence the voice of her dead twin sister, who was “absorbed into my tissues” in the womb. She hates school, where other kids mock her, as though her own self-disgust weren’t enough. After a blackly comic scene where she gets stuck in her bedroom doorframe like “an uncooperative cork”, she falls in love with the lonely carpenter who arrives to widen the door – but there are more twists to come. This powerful story is deeply physical, but driven by a compelling voice describing the torment of a girl who is “the psychical mirror of our time … immoderation made manifest”. 'The White Desert' by Luis López Carrasco The White Desert by Luis López Carrasco, translated by Rosalind Harvey (Granta, £14.99) This unpredictable book, comprising five linked stories about a Spanish couple, opens with the end of the world and gets weirder from there. A balloon debate about a post-apocalyptic scenario turns nasty when one participant pulls a knife, or thinks he does. A plane crash-lands on an island. “Can [we] go and get our luggage … Lots of people have, you know, soiled themselves.” What links the scenes is a sense of disconnection in our connected world, but the book subverts expectations: when a group of people celebrating New Year’s Eve go missing, it turns out to be a game of hide and seek. Footnotes peppered throughout suggest we’re viewing all this from the future (“Emirates was a well-known passenger airline …”), and discovering what the white desert is turns everything on its head. For readers who like to do their own joining up, and who want a playful, original take on our precarious lives, this is a thought-provoking treat. 'The Home of the Drowned' by Elin Anna Labba The Home of the Drowned by Elin Anna Labba, translated by Elizabeth Clark Wessel (Harvill, £16.99) “You could have waited, you bastards.” In 1942 Lapland, a village occupied by the semi-nomadic Sámi people is flooded by a new hydroelectric plant’s dam. One family watch as their goahti (peat-covered hut) disappears under the water. “It wasn’t the nicest goahti,” says Ánne. “No, but it was mine,” says her sister Rávdná. When Rávdná wants to build a house to replace it, the authorities refuse permission: the Sámi way of life has been rejected but alternatives are not permitted. A local newspaper half-heartedly offers to publicise their case, but “we receive a lot of angry letters if we use any foreign words”. When the government tells local people the new dam “will lift us out of poverty and injustice”, the words reek with irony. This intimate story of infuriating discrimination is, Labba says, based on real events in Sweden.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

Brighton & Hove Albion Women will take the field against Manchester City Women at Wembley on 31 May 2026 for the Women's FA Cup final. City aim to complete a first-ever double, while Brighton chase their inaugural major trophy, playing under the emotional weight of the recent passing of Rado Vidosic, the club’s former head of coaching. Brighton Chasing First Major Trophy Amid Tribute to Late Coach Rado Vidosic The match carries deep personal significance for Brighton. Rado Vidosic, who died from cancer four months earlier, was a pivotal figure in the club’s development. His son, Dario Vidosic, who grew up watching Wembley finals, now leads the team onto the pitch, honoring his father's legacy. Match Timing, Historical Context and Key Figures Kick‑off: 3:00 pm BST (13:00 GMT) City’s ambition: First domestic double in club history. Brighton’s goal: First Women’s FA Cup title since the competition’s inception. Key players: Khadija “Bunny” Shaw (City) – recently secured a four‑year contract extension; Ruth Keenan (Brighton) – leading scorer this season. Historical note: City have won the league this season; Brighton have never lifted the cup. Potential Shift in Women’s Football Power Balance A Brighton victory would signal a breakthrough for clubs outside the traditional powerhouses, potentially encouraging greater investment in smaller teams. Conversely, a City win would cement their dominance and could accelerate the professionalisation of the women's game across England, attracting more sponsors and media attention. What the Result Could Mean for Both Clubs If City wins: Reinforces their status as the premier English women’s side, boosting brand value and likely influencing future player recruitment. If Brighton wins: Provides a morale boost, validates the club’s development pathway, and may spur increased fan engagement and funding. Long‑term outlook: Either outcome will shape the narrative for the 2026‑27 season, affecting league dynamics, TV rights negotiations and grassroots participation.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The LeadMost men in the UK will not be offered prostate cancer screening if the government accepts the final recommendation of an expert committee. The UK National Screening Committee (UKNSC) has concluded that widespread screening using the prostate-specific antigen (PSA) test was "likely to cause more harm than good" despite prostate cancer being the most common cancer in the UK.The Recommendation DetailsThe committee recommended screening only for men with the BRCA2 gene variant who have a family history of certain cancers, suggesting they be screened every two years between the ages of 45 and 61. For this specific group, prostate cancer is more common, develops earlier, and can be more aggressive. Of 100 men with a BRCA2 variant, between 21 and 35 will develop prostate cancer before the age of 80.The committee recommended against screening for other at-risk groups, including black men, citing "ongoing uncertainty on whether screening would cause more good than harm." The main harms of population screening include incontinence and erectile dysfunction in men who do not need treatment for the disease.The Prevalence DataProstate cancer is the most common cancer in the UK, with more than 64,000 men diagnosed every year. However, there is currently no national screening programme for the disease. The UKNSC estimates that its final recommendation would lead to "a few thousand" men being screened for prostate cancer each year.Only around one in every 300 to 400 people will have BRCA gene variations, though as many as one in every 40 Ashkenazi Jewish people carry these variations. In England, the NHS offers free BRCA gene testing for anyone aged 18 or over who has at least one Jewish grandparent.The Impact AnalysisThe decision will come as a blow to campaigners who have voiced support for more widespread screening, including high-profile figures like Sir Chris Hoy, David Cameron, and Sir Stephen Fry. Prostate Cancer UK expressed being "deeply disappointed" with the recommendation, stating that without a screening programme for the UK's most common cancer, "we lose more than 12,000 dads, brothers and partners every single year."However, medical experts argue that screening can reduce deaths from prostate cancer only to a small extent and does not improve overall survival. The challenge remains that once a prostate cancer is found, doctors still can't reliably tell which cancers need treatment and which do not, and treatments can cause long-lasting harm.The Future OutlookThe government will now consider the recommendation, with the new Health Secretary James Murray set to meet with the UKNSC chair. The Department of Health and Social Care stated that Murray "will give full and careful consideration to the recommendation" and would update on the government's response shortly.The committee acknowledged that more research is needed to address evidence gaps, particularly regarding black men. The UKNSC will work with the Transform trial, launched by Prostate Cancer UK, to gather more data. It was noted as "particularly important" that a "sufficient number" of black men be invited to participate in this trial.

The Lead: A Provocative Debut Rozie Kelly's frank and feisty debut novel, Kingfisher, has been shortlisted for this year's Women's Prize for Fiction and begins with a case of lust at first sight. The unnamed narrator, a 35-year-old writer, becomes infatuated with a famous poet 17 years his senior, setting the stage for a complex exploration of desire, power dynamics, and unconventional relationships. The Novel's Premise: An Unconventional Attraction The novel introduces us to a "beautiful" 35-year-old writer in a complicated but loving relationship with the equally beautiful but somewhat boring Michael. The object of his sudden attraction is a renowned poet running a popular course at the same university. Despite barely knowing her, he experiences an intense desire "to be inside her," expressing surprise at his own reaction: "A woman! What was the world coming to?" The narrator's infatuation is initially fueled by the poet's success, wealth, and fame, though he also admits to wanting to subjugate her, "to push her down, to render her imperious intelligence stupid with the weight of my body." Thematic Exploration: Love, Lust, and Power Kelly shrewdly explores the different forms love and lust can take, complicated by shifting power dynamics. The relationship begins when the poet and narrator meet to discuss his (nonexistent) poetry collection, leading to an unexpected night together. As their relationship develops, particularly after the poet receives a terminal cancer diagnosis, they settle into the rhythms of a loving relationship. The narrative also explores the narrator's complicated relationship with his racist and homophobic mother, Hetty, confined to a care home, and his deteriorating relationship with Michael, who eventually leaves him for a younger partner. Narrative Structure: Stylistic Uncertainties Despite a confident start and intriguing premise, Kingfisher suffers from narrative inconsistencies. Interesting characters are established then forgotten, and narrative threads are never fully developed. The novel struggles with tonal shifts, moving from "bracing language and violent desires" to "bedside solicitude and quiet domesticity." A late-stage shift into gothic fantasy further destabilizes the narrative, with the ending dangerously approaching "it was all a dream" territory. Throughout, the narrator questions the nature of their relationship: "Who's using who here, do we think?" The answer, as presented in the novel, is that both characters are using each other, as "writers on the make; everyone is potential copy." Critical Assessment: Verve Without Fire Kingfisher possesses considerable verve and energy, demonstrating Kelly's willingness to take risks and embrace absurdity. The novel "crackles and sparks," but ultimately "never quite catches fire." While the book successfully challenges conventional narratives about love and desire, particularly through its exploration of non-traditional relationships and power dynamics, it fails to maintain its initial momentum. The narrative uncertainty and inconsistent tone prevent what could have been a groundbreaking exploration of contemporary relationships from achieving its full potential.

The Failure of US Garbage Incinerators The nation's garbage incinerators are largely failing to eliminate Pfas 'forever chemicals' air pollution, and are putting people in largely low-income neighborhoods at risk, public health advocates and independent experts warn. The Industry's Misleading Claims A new industry trade group report alleges Minnesota's incinerators are reducing their forever chemical emissions by 99.6%. However, experts say the report is full of bad assumptions, incomplete data, and misleading language. The Health Risks of Pfas Pollution Pfas are a class of at least 16,000 compounds that have been linked to cancer, birth defects, decreased immunity, high cholesterol, kidney disease, and a range of other serious health problems. They are dubbed 'forever chemicals' because they do not naturally break down in the environment. The Impact on Low-Income Neighborhoods The incinerators are often located in low-income neighborhoods, putting vulnerable populations at risk. 'This trash becomes the problem of the poor and marginalized to deal with in their bodies,' said Nazir Khan, executive director of the Minnesota Environmental Justice Table. The Need for Stricter Regulations Experts say that stricter regulations are needed to address the issue of Pfas pollution. 'I'm not aware of any industrial-scale commercial incinerator that solves this problem,' said Michael Youhana, an attorney with the non-profit Earthjustice.

Brighton & Hove Albion Women will walk out at Wembley on 30 May 2026 to face Manchester City in the Women’s FA Cup final, with coach Dario Vidosic dedicating the match to his father, Rado Vidosic, who died from cancer four months earlier.The Emotional Drive Behind Brighton’s FA Cup Final QuestVidosic, a former Australian midfielder, recalls childhood evenings watching Wembley finals with his father and says the lessons of perseverance he learned from Rado are guiding the squad. He stresses that the final is not just about a trophy but about giving his father a reason to be proud, a sentiment shared by the players and the Vidosic family who will be in the stands.Financial Stakes: £80 million Stadium Plan Highlights Club’s CommitmentBrighton’s recent announcement of a purpose‑built women’s stadium adjacent to the Amex, costing about £80 million and slated for an initial 10,000 seats, demonstrates the club’s long‑term investment in the women’s side. The facility is intended to nurture academy talent and provide a dedicated venue for future cup runs.Impact on Women’s Football in Brighton and BeyondThe Seagulls’ rise to their first major women’s final, after a dramatic semi‑final comeback against Liverpool, signals a shift in the competitive landscape of English women’s football. Success at Wembley could accelerate grassroots participation, especially among young girls inspired by Vidosic’s story and the club’s infrastructure plans.Looking Ahead: What a Victory Could Mean for the Seagulls and the GameA win would make Brighton the first club to bring a major trophy to the women’s side, cementing Vidosic’s legacy and potentially attracting further sponsorship and talent. Even without the silverware, the final serves as a platform to showcase the club’s ambition and the growing stature of the Women’s FA Cup.

Lead: Sleep Deprivation Emerges as a Possible Driver of Early-Onset CancerResearch presented at the American Society of Clinical Oncology’s annual meeting in Chicago suggests that irregular sleeping patterns could be a significant, yet modifiable, risk factor for cancers diagnosed before age 50.The Study Linking Sleep Disruption to Early-Onset CancerTwo investigations led by MD Anderson Cancer Center analysed health records of over 18 million U.S. adults aged 18‑50. Participants with chronic insomnia showed a markedly higher incidence of bowel, breast, uterine, and ovarian cancers compared with well‑rested peers.Key Numbers Highlight the Scale of the IssueGlobal early‑onset cancer cases rose from 1.82 million (1990) to 3.26 million (2019), an 80% increase in three decades.Cancer deaths among people in their 30s, 40s, or younger climbed 27% over the same period.In the MD Anderson cohorts, insomnia was associated with up to three‑fold higher cancer risk within five years.Why This Matters for Public Health and Clinical PracticeThe data position sleep quality alongside genetics and lifestyle as a potential lever for curbing the surge in early‑onset cancers. Experts caution that the studies show association, not causation, but note that sleep deprivation can impair immune function and promote behaviours (smoking, poor diet, reduced exercise) that are already linked to cancer.Looking Ahead: Research, Screening, and Prevention StrategiesStakeholders anticipate a wave of longitudinal studies to test whether improving sleep can lower cancer incidence. In the meantime, clinicians are likely to incorporate sleep assessments into risk‑stratification tools, while public‑health campaigns may emphasise sleep hygiene alongside anti‑smoking and sun‑safety messages.